Literature DB >> 15615654

Poorer survival of elderly patients with ovarian cancer: a population-based study.

P Petignat1, G Fioretta, H M Verkooijen, A T Vlastos, E Rapiti, C Bouchardy, G Vlastos.   

Abstract

OBJECTIVE: To compare ovarian cancer survival in elderly and young patients.
MATERIAL AND METHODS: Using the Geneva Cancer Registry, we identify women diagnosed with primary ovarian cancer between 1980 and 1998. We compared tumors characteristics, treatment patterns of young patients (<or=70 years) versus older patients (>70 years) by logistic regression. To evaluate the effect of age on prognosis, we compared disease specific survival by Cox proportional hazard analysis, taking into account other prognostic factors.
RESULTS: This study included 285 patient aged 70 years and 451<or=70 years. Older women presented more advanced stage and at equal stage were less often treated by optimal surgery and chemotherapy. Five-year of disease specific survival was 18% (95% CI: 13-23%) and 53% (95% CI: 48-58%) among old versus young women. Over ovarian mortality was only partly explained by these differences and after adjustment for tumor characteristics and treatment, older women still had a 1.8-fold increased risk of dying of ovarian cancer compared to younger (HR 1.8, 95% CI: 1.4-2.4).
CONCLUSION: Age strongly decreases ovarian cancer mortality. This over mortality is only partly explained by later diagnosis and suboptimal treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15615654     DOI: 10.1016/j.suronc.2004.08.010

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  11 in total

1.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Alexander B Olawaiye; James J Java; Thomas C Krivak; Michael Friedlander; David G Mutch; Gretchen Glaser; Melissa Geller; David M O'Malley; Robert M Wenham; Roger B Lee; Diane C Bodurka; Thomas J Herzog; Michael A Bookman
Journal:  Gynecol Oncol       Date:  2018-08-19       Impact factor: 5.482

3.  Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.

Authors:  Xiaoman Hou; Yali Zhai; Kevin Hu; Chia-Jen Liu; Aaron Udager; Celeste L Pearce; Eric R Fearon; Kathleen R Cho
Journal:  Gynecol Oncol       Date:  2022-04-09       Impact factor: 5.304

4.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22

Review 5.  Chemotherapy for ovarian cancer in the older adult.

Authors:  Christopher B Steer
Journal:  Curr Treat Options Oncol       Date:  2009-04-16

6.  Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.

Authors:  Mayumi Kobayashi Kato; Mayu Yunokawa; Seiko Bun; Tatsunori Shimoi; Kan Yonemori; Naoyuki Miyasaka; Tomoyasu Kato; Kenji Tamura
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-06       Impact factor: 4.553

Review 7.  Ovarian cancer cytoreductive surgery in the elderly.

Authors:  Ginger J Gardner
Journal:  Curr Treat Options Oncol       Date:  2009-08

8.  Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Authors:  Radoslav Chekerov; Philipp Harter; Stefan Fuxius; Lars Christian Hanker; Linn Woelber; Lothar Müller; Peter Klare; Wolfgang Abenhardt; Yoana Nedkova; Isil Yalcinkaya; Georg Heinrich; Harald Sommer; Sven Mahner; Pauline Wimberger; Dominique Koensgen-Mustea; Rolf Richter; Gülten Oskay-Oezcelik; Jalid Sehouli
Journal:  Gynecol Oncol Res Pract       Date:  2017-03-07

9.  Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Authors:  T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

10.  Under-treatment of elderly patients with ovarian cancer: a population based study.

Authors:  Elisabeth Fourcadier; Brigitte Trétarre; Claudine Gras-Aygon; Fiona Ecarnot; Jean-Pierre Daurès; Faïza Bessaoud
Journal:  BMC Cancer       Date:  2015-11-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.